Objective To clarify the clinical characteristics of type 2 diabetic patients with non-alcoholic fatty liver disease (NAFLD) and to assess whether NAFLD is related to angiopathy. Methods The study included 388 Japanese type 2 diabetic outpatients without viral hepatitis. The main outcome measures were angiopathy and NAFLD. Results The 388 subjects were divided into two subgroups based on alcohol consumption. Fatty liver was recognized in 36 of the 142 drinking patients (25%). There was no association of fatty liver disease with diabetic macro-or microangiopathy in these patients. Fatty liver disease (namely, NAFLD) was recognized in 77 of the 246 non-drinking patients (31%). Type 2 diabetic patients with NAFLD had a significantly younger age, higher body mass index level, higher levels of HbA1c, total cholesterol and triglyceride, lower HDL-C level, higher prevalence rates of hypercholesterolemia and obesity than counterparts without NAFLD. In addition, individuals in the elderly ( 65 years) non-drinking group with NAFLD had a significantly higher prevalence rates of diabetic macroangiopathy, coronary heart disease and thicker intima-media thickness level than their counterparts without NAFLD. The logistic regression analysis showed that NAFLD is an independent predictor of diabetic macroangiopathy. Conclusion NAFLD was associated with an increased prevalence of diabetic macroangiopathy and coronary heart disease in elderly patients. In addition, NAFLD is an independent predictor for diabetic macroangiopathy. These findings suggest that type 2 diabetic patients with NAFLD should be considered as a high risk group for developing macroangiopathy, even if macroangiopathy is not clinically detected.
Introduction
Fatty liver is very common, especially in overweight individuals. The prevalence of fatty liver disease (FLD) in the general population ranges from 10% to 24% in various countries (1) . FLD is a reversible condition where large vacuoles of triglyceride fat accumulate in liver cells, and sometimes cause serious liver problems. The liver has an important role in the regulation of metabolism. Several bolic syndrome (2) (3) (4) (5) . NAFLD encompasses a broad spectrum of liver diseases ranging from simple steatosis (fatty liver) to non-alcoholic steatohepatitis (NASH) and cirrhosis (6) (7) (8) . This metabolically derived liver disease is becoming a major problem in hepatology departments, and it is now recognized as the most common chronic liver condition in the Western world (6) . Jimba et al. showed that the prevalence of NAFLD was 29% in apparently healthy middleaged Japanese adults (9) . The majority of patients with NAFLD are overweight/obese or has type 2 diabetes; another commonly associated clinical feature is atherogenic dyslipidemia (i.e. high triglyceride, low HDL-cholesterol and increased small dense LDL-cholesterol levels). A great deal of evidence suggests that NAFLD is the hepatic manifestation of metabolic syndrome (10) . Notably, NAFLD is associated with insulin resistance even in non-obese and non-diabetic individuals, suggesting that NAFLD may be an early predictor of metabolic disorders and diseases in the normal-weight population (11) . Accordingly, the cardiovascular disease risk dictates the outcome of these patients more frequently and to a greater extent than does liver disease progression. Although NAFLD is recognized in type 2 diabetic patients with a relatively high frequency, the clinical characteristics of these patients are not sufficiently clarified. The present study sought to clarify the clinical characteristics of type 2 diabetic patients with NAFLD and to examine the association of NAFLD with diabetic angiopathy in these patients.
Materials and Methods

Ethics statement
This study was conducted according to the principles expressed in the Declaration of Helsinki. The Ethics Committees of Edogawa Hospital approved the protocol of this study and waived the need for written informed consent because the data were analyzed anonymously for this observation study based on the data stored in the hospital database.
Study patients
A total of 388 Japanese type 2 diabetic outpatients were selected from all outpatients that presented from 2007 to 2008 (n=1,307) for the study. A total of 919 patients were excluded because a physical measurement was missed, abdominal ultrasonography was not performed or their alcohol drinking habit was unclear. All participants were asked about their medical history and alcohol consumption, and underwent a physical examination. Alcohol consumption was determined with a question that was embedded in the health interview self-report questionnaire. The patients were asked to indicate whether they drank alcohol or abstained (yes/no) and if they indicated that they did drink, to describe how many drinks they daily consumed in a given volume of alcohol in ethanol equivalents (! 20 g/>20 g daily). The present study defined the patients drinking >20 g ethanol equivalents/day as 'drinking patients'. Patients drinking alcohol ! 20 g/day or abstainers were defined as 'non-drinking patients'. NAFLD was defined as a fatty liver detected by abdominal ultrasonography in individuals whose consumption of alcohol was ! 20 g daily or abstainers (12) . Blood sampling, routine medical examinations of their glycemic control and chronic diabetes complications, abdominal ultrasonography, echo-Doppler scanning of carotid arteries, measurement of ankle brachial pressure index (ABI) and brachial-ankle pulse wave velocities (baPWV) were also performed for all participants.
Clinical measurements and laboratory procedures
Body mass index (BMI) was calculated by dividing the weight in kilograms by the height in meters squared. The blood pressure was measured twice with the subjects in a sitting position after a 5-minute rest. The lower value of the two measurements was used for the study. Hypertension was defined as a systolic blood pressure " 140 mmHg and/or a diastolic blood pressure " 90 mmHg. The participants currently using antihypertensive medications were also classified as positive for hypertension. Information on daily alcohol consumption and current use of medications was obtained from all participants by a questionnaire. Sixty-three percent of the participants (n=246) were abstainers or drank minimally (alcohol consumption ! 20 g/day). Thirty-seven percent (n=142) of participants were moderate or heavy drinkers (alcohol consumption >20 g/day).
Venous blood measurements were performed by standard laboratory procedures. Most participants had serum liver enzymes within the reference ranges in our laboratory, which for aspartate aminotransferase (AST), alanine aminotransferase (ALT) and γ-glutamyltransferase (GGT) activities were 10 to 35 U/L for women and 10-50 U/L for men. Triglycerides were measured at any time, either after fasting or after a meal. No participants had seropositivity for viral hepatitis B and C. The HbA1c levels were determined by high performance liquid chromatography using an automated HLC-723G7 analyzer (Tosoh Corporation, Tokyo, Japan) and calibrated by the Japan Diabetes Society (JDS) standard calibrators. The value for HbA1c (%) is estimated as a National Glycohemoglobin Standardization Program (NGSP) equivalent value (%) calculated by the formula: HbA1c = HbA1c (JDS) + 0.4, considering the relational expression of HbA1c (JDS) measured by the previous Japanese standard substance and measurement methods and HbA 1 c (NGSP) (13) . The estimated glomerular filtration rate (eGFR) was calculated using the formula reported by Matsuo et al. (14) . This equation originated from the MDRD study group (15) adjusted for Japanese individuals, and recommended by the Japanese Society of Nephrology: eGFR (mL/min/1.73m
2 )=194×Scr -1.094 ×Age -0.287 ×0.739 (if female). Hypercholesterolemia was defined by serum concentrations of total cholesterol " 220 mg/dL, LDL-cholesterol " 140 mg/ dL or as patients already being treated with lipid-lowering agents.
The ankle brachial pressure index (ABI) and brachialankle pulse wave velocities (baPWV) were measured as indicators of atherosclerosis using Form PWV/ABI, BP-203 PRE II (Omron Colin Co., Ltd., Bunkyo, Tokyo, Japan). The intima-media thickness (IMT) of the carotid artery was measured with ultrasonographic examinations by skilled laboratory technicians using Aplio XV ultrasound machine (Toshiba Medical Systems Corp., Ohtawara, Tochigi, Japan). B-mode imaging of the carotid artery and examination of IMT was performed as described in our previous report (16) . Although the carotid IMT increases with age, it does not rise above 1.0 mm in normal Japanese adults. Therefore, the presence of increased IMT (IMT thickening) in the carotid artery has been defined as an IMT of " 1.1 mm (17) .
Assessment and definition of diabetic microangiopathy was based on the following criteria. Diabetic nephropathy (DN) was staged according to an analysis of a spot urine sample as: DN stage I (normoalbuminuria), albumin/creatinine ratio (ACR) <30 mg/g creatinine; DN stage II (microalbuminuria), 30 ! ACR <300 mg/g creatinine; DN stage III (macroalbuminuria), ACR " 300 mg/g creatinine (or dipstick urinalysis revealed 2+, 3+ or 4+) and eGFR " 30 mL/ min/1.73m 2 ; and DN stage IV, ACR " 300 mg/g creatinine (or dipstick urinalysis 2+, 3+ or 4+) and eGFR <30 mL/ min/1.73m 2 . Diabetic retinopathy was defined as simple retinopathy or as more severe conditions, which were judged according to the results of a fundoscopic examination performed by expert ophthalmologists. Diabetic neuropathy was diagnosed by the presence of two or more components among clinical symptoms (bilateral spontaneous pain, hypoesthesia, or paresthesia of the legs), the absence of ankle tendon reflexes and decreased vibration sensations using a C 128 tuning fork.
Assessment and definition of diabetic macroangiopathy was based on the following criteria. Coronary heart disease (CHD) was diagnosed based on a previous history of myocardial infarction, angina pectoris, electrocardiogram abnormalities suggesting myocardial ischemia or intervention after coronary angiographic examination. Cerebrovascular disease (CVD) was diagnosed by the physicians as a history of an ischemic stroke using brain computed tomography or magnetic resonance imaging. Only the patients with symptoms were classified as having cerebrovascular disease, and cases of silent brain infarction, transient ischemic attack or brain hemorrhage were excluded from this study. Peripheral arterial disease (PAD) was diagnosed by the absence of a pulse in the legs along with ischemic symptoms, obstructive findings on an ultrasonographic examination of the lower extremities, or ankle-brachial pressure index (ABI) <0.9. The present study defined 'diabetic macroangiopathy' as a generic concept of large blood vessel disorders including either CHD, CVD or PAD in diabetic patients.
Statistical analysis
Data are shown as the means ± SD. Clinical characteristics were compared by two-tailed unpaired t-tests or a oneway analysis of variance for continuous variables, and the chi-squared test for categorical variables. Differences with p values of less than 0.05 were considered to be statistically significant. The JMP statistical software package, version 8.0, (SAS Institute, Cary, NC, USA) was used to perform all analyses.
Results
Three hundred eighty-eight patients were analyzed. They were divided into two groups based on their alcohol consumption, the drinking group (n=142) and the non-drinking group (n=246). Table 1 shows the clinical characteristics of the patients in each group. The percentage of alcohol drinking was significantly less in the female participants (12 vs. 46%, p<0.01). Drinking patients had a younger age at onset of diabetes (51±10 vs. 54±10 years, p<0.05), higher GGT level (70±88 vs. 44±101 U/mL, p<0.05) and a higher HDL-C level (64±19 vs. 57±15 mg/dL, p<0.01) than non-drinking patients. Thirty-six of the 142 drinking patients developed fatty liver disease. Seventy-seven of the 246 non-drinking patients developed FLD. The prevalence of FLD was 25% and 31%, respectively, and there was no significant difference between these subgroups. Table 2 shows the clinical and biochemical characteristics of the four subgroups; drinking patients with FLD, drinking patients without FLD, non-drinking patients with FLD and non-drinking patients without FLD. Drinking type 2 diabetic patients with FLD had significantly higher BMI level (26.2± 4.0 vs. 23.1±4.0 kg/m 2 , p<0.01) and higher rates of obesity (56 vs. 23%, p<0.01) than their counterparts without FLD. There was no significant difference between these two subgroups in other variables including the lipid profile. No association of FLD was recognized with macro-or microangiopathy in drinking type 2 diabetic patients. The non-drinking type 2 diabetic patients were divided into four subgroups to adjust for the influence of the patients' age; elderly patients (age " 65 years) with NAFLD, elderly patients without NAFLD, nonelderly patients (age ! 64 years) with NAFLD and nonelderly patients without NAFLD. Fig. 1 shows the prevalence rates of diabetic macroangiopathy in each subgroup. As shown in Fig. 1a , there was no significant difference in the prevalence rates of macroangiopathy, CHD, CVD and PAD between the nonelderly, non-drinking type 2 diabetes patients with NAFLD and those without NAFLD. Elderly non-drinking type 2 diabetic patients with NAFLD had significantly higher prevalence rates of macroangiopathy and CHD than counterparts without NAFLD (Fig. 1b) . Fig. 2 shows the measurements of IMT, baPWV and ABI in these four subgroups. The IMT was significantly thicker in elderly patients with NAFLD than in their counterparts without NAFLD. The numerical value of baPWV, another predictor of atherosclerosis, had a tendency to be higher in elderly patients with NAFLD than in counterparts without NAFLD (p>0.05). The non-drinking type 2 diabetic patients were divided into four subgroups to investigate the influence of obesity on macroangiopathy; non-obese patients (BMI <25 kg/m 2 ) with NAFLD, non-obese patients without NAFLD, obese patients (BMI ! 25 kg/m 2 ) with NAFLD and obese patients without NAFLD. Fig. 3 shows the prevalence of diabetic macroangiopathy in each subgroup. There was no significant difference in the rates of macroangiopathy, CHD, CVD and PAD between the non-obese, non-drinking type 2 diabetes patients with NAFLD and those without NAFLD. Obese non-drinking type 2 diabetic patients with NAFLD had significantly higher rates of macroangiopathy, CHD and PAD than their counterparts without NAFLD (Fig. 3b) . Although IMT, baPWV and ABI were also measured in these four subgroups, there were no significant differences.
Furthermore, the non-drinking type 2 diabetic patients were divided into four subgroups to investigate the influence of sex on macroangiopathy; male patients with NAFLD, male patients without NAFLD, female patients with NAFLD and female patients without NAFLD. Fig. 4 shows the rates of diabetic macroangiopathy in each subgroup. There was no significant difference in the rates of macroangiopathy, CHD, CVD and PAD between the male, non-drinking type 2 diabetes patients with NAFLD and those without NAFLD. Female non-drinking type 2 diabetic patients with NAFLD had significantly higher rates of macroangiopathy, CHD than their counterparts without NAFLD (Fig. 4b) . Although the IMT, baPWV and ABI were also measured in these four subgroups, there were no significant differences. Table 3 shows the association of clinical variables with macroangiopathy determined by a logistic analysis in nondrinking type 2 diabetic patients. Fatty liver was significantly and independently associated with diabetic macroangiopathy (p=0.02).
Discussion
This study clarified the clinical and biochemical characteristics of type 2 diabetic patients with FLD including NAFLD. First, we found no association between FLD and the prevalence ratios of macro-and microangiopathy in drinking type 2 diabetic patients. We showed that drinking type 2 diabetic patients with FLD had a significantly higher BMI level, higher rates of obesity and hypercholesterolemia than those without FLD. As shown in Table 2 , these differences were also recognized in non-drinking type 2 diabetic patients, but the lipid profiles were different between the drinking group and non-drinking group. Non-drinking patients with FLD had a significantly higher TC level, lower HDL-C level and higher TG level than their counterparts without FLD. On the other hand, the TC level, HDL-C level and TG level showed no difference between drinking type 2 diabetic patients with FLD and those without FLD. Alcohol drinking may therefore have an anti-atherogenic effect on blood vessels by altering the lipid profile. Further investigation is necessary to ascertain the influence of alcohol drinking on angiopathy.
The non-drinking patients were examined in detail by dividing these patients into two subgroups, patients with fatty liver (NAFLD) and patients without fatty liver. Type 2 diabetic patients with NAFLD had a significantly younger age, higher levels of BMI, HbA1c, TC and TG, lower HDL-C level and higher prevalence rates of obesity and hypercholesterolemia than their counterparts without NAFLD. Previous studies noted that NAFLD is associated with insulin resistance and metabolic syndrome (obesity, combined hyperlipidemia, type 2 diabetes mellitus and high blood pressure) (18, 19) . These clinical characteristics were also recognized in type 2 diabetic patients with NAFLD in the current series, though they had a relatively long duration of diabetes (~10 years). Jimba et al. reported that NAFLD is associated with impaired glucose metabolism in Japanese adults (9) . They also showed that NAFLD is independently associated with an increasing fasting plasma glucose level even in nondiabetic individuals. In fact, type 2 diabetic patients with NAFLD possessed several factors of metabolic syndrome in the current study. Consequently, it is possible that type 2 diabetic patients with NAFLD had gradually developed diabetes on the basis of impaired glucose metabolism, especially insulin resistance. Several studies have shown that there is an association of NAFLD with CHD (20, 21). The current findings were somewhat consistent with the previous data, but clearly showed that the prevalence of CHD was significantly increased in elderly (age ! 65 years) type 2 diabetic patients with NAFLD than in those without NAFLD (Fig. 1b) . In addition, elderly type 2 diabetic patients with NAFLD had a significantly thicker carotid IMT level than the counterparts without NAFLD (Fig. 2b) . Targher demonstrated that the increase of carotid artery wall thickness is associated with the histological severity of NAFLD (22) . These findings suggest that the degree of hepatic damage by NAFLD could be more severe in elderly patients than in nonelderly patients. We also demonstrated that the prevalence of macroangiopathy and CHD was significantly increased in obese type 2 diabetic patients with NAFLD (Fig. 3b) . These results were very similar to the results shown in Fig. 1b , suggesting that NAFLD is frequently associated with obesity. Furthermore, the prevalence of macroangiopathy and CHD significantly increased in female type 2 diabetic patients with NAFLD (Fig. 4b) . The cause and effect of these differences was unclear, and further investigation is therefore necessary to ascertain the influence of sex on diabetic macroangiopathy. Although both obesity and sex were considered to be important factors for developing macroangiopathy, a multivariate regression analysis showed that the presence of NAFLD was independently associated with increasing macroangiopathy in non-drinking type 2 diabetic patients (Table 3) .
What is the common factor associated with NAFLD, atherosclerosis and impaired glucose metabolism? Insulin resistance could be a potential answer to that question. Insulin resistance is associated with the development of atherosclerosis and macroangiopathy (23, 24) . In addition, insulin resistance is closely associated with FLD including NAFLD (6) . The development of type 2 diabetes mellitus is characterized by not only insulin resistance but also impaired beta-cell function. Although insulin resistance is an important pathogenic factor of type 2 diabetes mellitus, it is important to pay attention to insufficient insulin secretion especially in Japanese patients. Japanese often develop type 2 diabetes mellitus based on insufficient insulin secretion, not insulin resistance (25, 26) . Therefore, Japanese type 2 diabetic patients with NAFLD may have a distinct feature characterized by insulin resistance. The clinical index for insulin resistance, such as HOMA-IR was not examined in the current study, because the subjects of this study were outpatients (they did not always present in a fasting state). Closer observation is expected to reveal the influence of insulin resistance in these patients. The current findings suggest that type 2 diabetic patients with NAFLD should be considered as a high risk group for developing macroangiopathy, even if macroangiopathy is not detected clinically. Further investigation is necessary to ascertain whether there is a timedependent effect of NAFLD in these patients.
In conclusion, NAFLD is significantly associated with diabetic macroangiopathy. Type 2 diabetic patients with NAFLD (especially, if they are elderly) require intensive examination to assess macroangiopathy, even if it is not detected clinically.
The present study had several important limitations. First, it was a small, cross-sectional study that was unable to show a causal relation between the higher incidence of macroangiopathy and NAFLD. Validation of the current results and further elucidation of the potential mechanisms involved are, therefore, essential. Second, the presence of fatty liver was determined only once in clinical practice. Although patients with viral hepatitis were excluded from the study, it would have been better to check the severity of FLD in periodic medical examinations.
Conclusion
This study clarified the clinical characteristics of type 2 diabetic patients with NAFLD. NAFLD was significantly associated with an increased prevalence of macroangiopathy, especially coronary heart disease in elderly patients. This study also found that NAFLD was independently associated with macroangiopathy in non-drinking type 2 diabetic patients. These findings suggest that type 2 diabetic patients with NAFLD should be considered as a high risk group for developing macroangiopathy, even if macroangiopathy is not detected clinically.
The authors state that they have no Conflict of Interest (COI).
